Form 4 for NAUT Nautilus Biotechnology, Inc.
Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-29 · accession 0001808805-25-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-02 | 2025-05-29 | NAUT | Mowry Anna | CFO, Treas | P - Purchase | $0.77 | +15.0K | 83.0K | +22% | +$11.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-29 | P | A | 15,000 | $0.77 | 83,000 | D | — | — | (F1) Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $0.7662 to $0.7489 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. (F2) Includes the following shares of Common Stock acquired through the Issuer's 2021 Employee Stock Purchase Plan: (i) 1,250 shares on December 1, 2022; (ii) 1,250 shares on June 1, 2023; (iii) 1,250 shares on December 1, 2023; (iv) 2,500 shares on May 31, 2024; (v) 2,500 shares on November 29, 2024; and (vi) 2,500 shares on May 30, 2025. |